Holen Sie sich die Stockscreener-App
29.40
0.27%
-0.08
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
Price to earnings ratio of Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh – HAN:6YG - TradingView
DBVT Stock Price, Quote & News - Syfe
Editas Medicine, Inc. (EDIT) Stock Price & News - Syfe
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh - TradingView
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – HAN:6YG - TradingView
Form 8K Immunocore Holdings plc For: 14 September By Investing.com - Investing.com South Africa
Immunocore Achieves Full Enrollment in Phase 3 TEBE-AM Melanoma Study - Kalkine Media
Immunocore at cantor global healthcare conference: growth, trials and cash - Investing.com
Prime Medicine, Inc. (PRME) Stock Price & News - Syfe
GENB Stock Price and Chart — NASDAQ:GENB - tradingview.com
Immunocore (IMCR) Technicals: Closes 1.65% Higher at $36.88 for the Current Session; Range View - dars.gov.et
Immunocore (IMCR) Technicals: Closes 1.65% Higher at $36.88 for the Current Session; Range View - dars.gov.et
ProKidney Corp. Class A (PROK) Stock Price & News - Syfe
Immunocore (IMCR) Earnings Review: The Available Earnings Metric Delivers a Miss; Share-Price Check: Shares Finish 2.77% Up at the CloseEarnings Surprise Stocks - careplusvn.com
Immunocore (IMCR) Earnings Review: The Available Earnings Metric Delivers a Miss; Share-Price Check: Shares Finish 2.77% Up at the CloseEarnings Surprise Stocks - dars.gov.et
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - MarketBeat
Q3 Earnings Forecast for Immunocore Issued By HC Wainwright - MarketBeat
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum - Yahoo Finance
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation? - Yahoo Finance
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss - TradingView
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - TradingView
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - Zacks Investment Research
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance Singapore
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Zacks Investment Research
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
Immunocore Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Immunocore posts Q2 2026 revenue beat as EPS misses - Investing.com
Immunocore Holdings earnings missed by $0.03, revenue topped estimates - Investing.com
Immunocore set to report earnings ahead of pivotal trial data - Investing.com
Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Stempoint Capital LP Purchases New Shares in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eversept Partners LP Takes Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Yahoo! Finance Canada
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Zacks Investment Research
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? - TradingView
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead - TradingView
IMCR|Immunocore Holdings PLC|Price:32.000|Chg%:-0.300 - TradingKey
Principal Financial Group Inc. Sells 139,306 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors - TradingView
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push - TradingView
Is it a good idea to invest in Immunocore stock right now? - MSN
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - TradingView
3.29%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):